[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 2
First page : ( 513) Last page : ( 515)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00090.8

Clinical Evidence of Regorifenib in Metastatic Colorectal Cancer: A Case Report

Mathew K. Sukanya1, Thomas Anjana1, Roshni P R2,*, Sivadas Akhila3, Pavithran K3

1Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidhyapeetham Kochi, Kerala, India

2Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidhyapeetham University AIMS Health Science Campus, Kochi-682041, Kerala, India

3Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidhyapeetham University AIMS Health Science Campus, Kochi-682041, Kerala, India

*Corresponding Author E-mail: roshnipr@aims.amrita.edu

Online published on 18 April, 2019.


Regorafenib {first small-molecule multikinase inhibitor 3} is used for patients who had earlier treatment with multiple regimens for metastatic colorectal cancer. Here we address a female patient who is 45 year old who had stage III disease with carcinoma recto sigmoid and hemicolectomy. From November 2012 to May 2013, patient had 12 cycles of FOLFOX regimen as adjuvant chemotherapy and it got relapsed after 7 months, later on, 6 cycles of Irinotecan 6 5FU/LV/Avastin as a second line agent was administered. From December 2013-May 2014, she had a 6 months of PFS. On her next follow up, she showed relapse of the disease in USG abdomen and PET scan and hence initiated on regorifinib with a dose of 160 mg once daily as the third line therapy. On development of jaundice and hand foot syndrome after 2 weeks of treatment, the dose was reduced to 80mg 2 tablets/day. As she was tolerating well with the decreased dose and showed good clinical response, she was advised for regular follow up. After 22 months of revaluation, it was observed that rising CEA and CT scan showed progressive disease, hence the treatment was changed to capecitabine. Even after 50 months from the diagnosis of disease, she is still continuing in good performance status 5. The patients survival period were less than 6 months only, before the availability of these newer targeted and chemotherapuetic agents. We emphasize the fact that Regorafenib plays an significant role in the treatment of refractory metastatic colorectal cancer patients as a third line agent with meaningful improvement in the survival and minimum side effects.



1. Progression Free Survival (PFS), 2. Regorafenib.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
751,627,980 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.